Genes: POMC, proopiomelanocortin; PC1, prohormone convertase 1; MC4R, melanocortin 4 receptor; Pcskl, proprotein convertase subtilisin/kexintype 1; SIM1, single-minded family bHLH transcription factor 1; BDNF, brain-derived neurotrophic factor; Pmch, promelanin concentrating hormone; NTRK2
, neurotrophic receptor tyrosine kinase 2; SNRPN, small nuclear ribonucleoprotein polypeptide N; SNURF, SNRPN upstream reading frame.
In the current study, the NTRK2
gene, which encodes TrkB in humans, was specifically downregulated in DPN patients but not in DM patients, thus strongly suggesting that downregulation of the BDNF-TrkB signaling pathway is associated with DPN.
Our results also show that some DE-transcripts are involved in signal transduction (Tables 4 and 5), among which, NTRK1, NTRK2, P2RX4, and P2RY2 are overlapped in multiple enriched GO terms (Table 5).
Ntrk1, also named TrkA, and Ntrk2 TrkB, are two members of the neurotrophic tyrosine kinase receptor (NTKR) family.
codes for a receptor of the BDNF protein, which is known to be related to BMI and is associated with the eating disorder anorexia.
(13,22) Following consideration of an alternative diagnostic category, we then use a combination of mutation and DNA copy number testing to identify cardinal mutations or chromosomal rearrangements involving such genes as BRAF, FGFR1, MYB/L1, NTRK2
, and PIK3CA.
The neurotrophic tyrosine kinase receptors NTRK1 (tropomyosin receptor kinase A [TRKA]) and NTRK2 (TRKB) belong to a family of nerve growth factor receptors that influence many aspects of neuronal development, including promoting proliferation and survival.
Immunohistochemical expression of NTRK1 and NTRK2 has been reported as strong in tissues exhibiting squamous differentiation but is less consistent or absent in glandular tissues, (11) suggesting that these markers may be effective discriminators between squamous and glandular subtypes of non-small cell lung carcinoma.
2508) and monoclonal rabbit anti-human NTRK2 (clone 80G2, catalog no.
What constitutes positive NTRK1 and NTRK2 immunohistochemical staining is not well defined.
To be included in the statistical analysis, each lung cancer case required at least 30 days of follow-up information and interpretable scores for both NTRK1 and NTRK2 immunostaining.
NTRK1 and NTRK2 Expression in Normal and Non-Lung Tumor Tissue